| Autor: |
Young DL; Entelos Inc., 110 Marsh Drive, Foster City, CA 94404, USA., Ramanujan S, Kreuwel HT, Whiting CC, Gadkar KG, Shoda LK |
| Jazyk: |
angličtina |
| Zdroj: |
Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2006 Oct; Vol. 1079, pp. 369-73. |
| DOI: |
10.1196/annals.1375.057 |
| Abstrakt: |
Anti-CD3 antibody therapy, a promising clinical approach for the treatment of type 1 diabetes (T1D), was investigated using a mathematical model of T1D in the female nonobese diabetic (NOD) mouse. Analyses of model simulation results indicate that, in addition to the known direct effects of anti-CD3 antibody on T lymphocytes, two additional mechanisms are required for sustained disease remission: (a) rapid regrowth of healthy beta cells following clearance of islet inflammation and (b) enhanced regulatory T cell activity and/or phenotypic changes in antigen presenting cells (APCs) that promote a stable regulatory environment in the pancreas. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
